Meeting
2022 ASCO Annual Meeting
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.
Authors
Nick Pavlakis
Northern Cancer Institute, St. Leonards, Sydney, Australia
Nick Pavlakis , David Turner Ransom , David Wyld , Katrin Marie Sjoquist , Kate Wilson , Val Gebski , James Murray , Andrew Ddembe Kiberu , Matthew E. Burge , William Macdonald , Paul Roach , David A. Pattison , Patrick Butler , Timothy Jay Price , Michael Michael , Benjamin James Lawrence , Dale L. Bailey , Simone Leyden , John Raymond Zalcberg , Harvey Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
ACTRN12615000909527
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4122)
DOI
10.1200/JCO.2022.40.16_suppl.4122
Abstract #
4122
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
First Author: Nick Pavlakis
Poster
2020 Gastrointestinal Cancers Symposium
First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).
First Author: Nick Pavlakis
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of O6-methylguanine-DNA methyltransferase (MGMT) status in pancreatic neuroendrocrine tumors with capecitabine and temozolomide (CAPTEM).
First Author: Eduardo Terán Brage Sr.